Deals review
- Deals review
- Deal details
AVI BioPharma Announces NeuGene Antisense Collaboration With USAMRIID on Biodefense Agents
In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.
Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Related deals
AVI BioPharma completes clinical trials
NEUGENE antisense drug enters human clinicals
Antisense agents block human prostate cancer cells
AVI BioPharma and International Therapeutics In Research Agreement
AVI BioPharma receives notice of grants
AVI BioPharma present polycystic kidney disease findings
AVI awarded grant from National Cancer Institute
AVI BioPharma And Gene Tools expand license agreement
AVI BioPharma Announces Termination of Cardiovascular Agreement With Medtronic
Related categories
- Therapeutic target
- Infectious diseases
- Industry sector
- Biotechnology
- Human therapeutics
More deals
Latest deals
- Biovator and BASF sign technology development agreement
- Agfa HealthCare signs four-year agreement with Chinese partners for distribution of radiography solutions, potentially worth 500 million US dollar
- Omnicare Announces Acquisition of Continuing Care Rx
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- GreenVax Selects Xcellerex XDR Single-Use Bioreactors for New Vaccine and Biotherapeutics Program
Most viewed deals
- Recommended acquisition of Acambis plc ("Acambis") by Sanofi Pasteur Holding ("Sanofi Pasteur") by way of scheme of arrangement Posting of Scheme Document
- Omnicare Announces Acquisition of Continuing Care Rx
- Bayer CropScience and Janssen PMP conclude research agreement:
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- Biovator and BASF sign technology development agreement
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us